Founded in 2014 and pivoting to prescription skincare in 2019, Musely enables patients to access prescription products via asynchronous consultations with board-certified dermatologists and OB-GYNs. The company focuses on compounded treatments across skin, hair, and menopause care. Musely has been cash-flow positive for years and reports average revenue growth of about 50% year-over-year. It has served over 1.2 million patients to date. Musely has been capital-efficient, having raised $20 million in 2014 from DCM and other investors and not taking equity capital since. With the new non-dilutive capital from CVF, Musely plans to scale sales, marketing, and customer acquisition to accelerate growth.

Total raised

$406M

Funding rounds

3

Latest round

Equity

Latest activity

Dec 2021